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Abstract
The treatment of hyperthyroidism is targeted at reducing the production of
thyroid hormones by inhibiting their synthesis or suppressing their release, as
well as by controlling their influence on peripheral tissue (conservative therapy,
medical treatment). Radical treatment includes surgical intervention to reduce
the volume of thyroid tissue or damage of the mechanisms of thyroid hormone
synthesis by radioiodine (131I) administration. Radioiodine ( 131I) is a reactor
radionuclide, produced as a result of uranium decomposition and emission of
β and γ radiation. The therapeutic effects of the isotope are obtained by the
emission of β radiation. In the paper, the effects of administered drugs
(antithyroid, glucocorticosteroids, lithium carbonate, inorganic iodine, β-blockers)
on the final outcome of radioiodine therapy in patients with hyperthyroidism
are discussed.
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Hyperthyroidism is a syndrome of clinical and biochemical symptoms,
resulting from the exposure of tissues to an excess of thyroid hormones:
thyroxine (T4) and triiodothyronine (T3). The thyroid gland is usually the
source of excessive production of thyroid hormones, other tissues being
less responsible for this production. Diffuse goitre (in Graves’ disease) is
most frequently at the base of hyperthyroidism, multinodular goitre holding
the second position in the ranking of hyperthyroidism causes, while the
third place is occupied by the autonomous single thyroid nodule.
Although the causes of hyperthyroidism may vary, the symptoms
resulting from the excess of free thyroid hormones – FT4 (free thyroxine)
and FT3 (free triiodothyronine) – in the circulation, as well as their actions
on cell receptors in target tissue and organs, are similar in all the identified
forms of hyperthyroidism.
They result from increased activity of the sympathetic part of the
autonomous nervous system and from enhanced catabolism. The usually
observed symptoms include: body weight decrease, increased appetite,
warmth  intolerance,  hyperhidrosis,  and  symptoms  associated  with
stimulation of the nervous system: irritability, anxiety, tremor of hands,
weakened muscular power, and excessive fatigability. Usually, additional
symptoms from the circulation are also observed, such as tachycardia,
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increased systolic pressure, and frequent rhythm
disorders – mainly atrial fibrillation. In elderly
patients, circulatory disturbances may be the only
symptoms of hyperthyroidism. Additionally, hair
loss, brittleness of the nails, more frequent rhythm
of bowel emptying and a tendency towards rare
menstruation in women may also be observed. 
In the case of hyperthyroidism in the course of
Graves’ disease, symptoms of orbitopathy may also
appear.
The treatment of hyperthyroidism is targeted at
reducing the production of thyroid hormones by
inhibiting their synthesis or suppressing their
release, as well as by controlling their influence on
peripheral tissue (conservative therapy, medical
treatment). Radical treatment includes surgical
intervention to reduce the volume of thyroid tissue
or damage of the mechanisms of thyroid hormone
synthesis by radioiodine ( 131I) administration. 
Radioiodine  ( 131I)  is  a reactor  radionuclide,
produced as a result of uranium decomposition and
emitting β and γ radiation. The therapeutic effects
of the isotope are obtained by the emission of 
β radiation. The radiation dose absorbed by the
thyroid stimulates the formation of free radicals,
which  damage  DNA  structure,  causing  either
cellular death or loss of its growth and division
abilities. 
Radioiodine  therapy  is  a method  of  choice
applied in the case of a single autonomous toxic
nodule.  Radioiodine  should  be  a first-stage
treatment in Graves’ disease in the hyperthyroid
state or after relative euthyroidism is attained by
means of short-term therapy with antithyroid drugs.
In the toxic nodular goitre (also in Graves’ disease),
radioiodine is used when administered antithyroid
drugs either fail or are not tolerated or their use is
contraindicated,  as  well  as  in  cases  of  hyper-
thyroidism  recurrence  after  operation  or  as
prophylactic treatment in the thyrocardiac syndrome
and in cases of contraindications to surgery or
patient’s refusal of operation. Radioiodine treatment
may sporadically be administered in patients with
subclinical hyperthyroidism, if autonomous foci have
been identified in scintigraphic imaging.
Absolute contraindications to radioiodine therapy
include: gestation, breast feeding and suspected
thyroid malignancy. On the other hand, relative
contraindications may be such as: low iodine uptake
by the thyroid, hyperthyroidism with high hormonal
values, leading to risk of thyroid crisis, the presence
of  “cold”  nodules  in  scintigraphic  evaluation,
together with the result of fine-needle aspiration
biopsy (FNAB), indicating a benign lesion and,
eventually, infiltrative orbitopathy in Graves’ disease
in its active phase. 
The  patient’s  preparation  for  radioiodine
treatment includes the following steps:
• withdrawal of preparations containing iodine and
iodides (expectorant agents or Lugol’s solution 
3 weeks before the onset of therapy, radiological
contrasting agents 4 weeks before the therapy,
amiodarone 4-6 months before the planned onset
of radioiodine administration); the recommended
period of withdrawal of applied thyrostatic agents
varies among different centres, being a subject
of debate for many authors; 
• exclusion of pregnancy; 
• medical  history  of  the  patient  and  physical
examination, evaluation of the hormonal status
(measurement of thyrotropin [TSH], FT4 and FT3
concentrations, as well as of antiTSHR antibodies
[less frequently, also antiTPO] in the case of
Graves’ disease), dosimetric studies, sonographic
imaging of the thyroid gland, and fine-needle
aspiration biopsy (FNAB) in the case of focal
changes. 
Radioiodine treatment is administered at nuclear
medicine  centres  authorised  to  use  131I.  The
treatment protocol requires in-patient conditions
when the activity of 131I exceeds 800 MBq.
In the treatment of benign thyroid diseases,
several ways of radioiodine administration have
been practised:
• administration of constant activity, empirically
determined on the basis of the degree of severity
of hyperthyroidism symptoms [1];
• administered  activities  are  determined  with
regards to thyroid mass [2];
• administered activities are calculated on the basis
of goitre mass, the assumed activity per 1 g of
thyroid tissue and iodine uptake by the thyroid
after 24 h [3];
• calculation of administered activity, based on
thyroid mass, the assumed absorbed dose, the
maximal iodine uptake and the effective half-life
(EHL) of iodine in the thyroid [4].
In the last two models of radioiodine therapy,
several dosimetric parameters have been identified,
on  the  basis  of  which  the  isotope  activity  is
calculated, namely: 
1) iodine uptake – the degree of radioiodine ( 131I)
accumulation,  expressed  as  the  percent  of
provided diagnostic activity;
2) thyroid mass – estimated in approximation on
the basis of data obtained from ultrasound
imaging of the thyroid gland;
3) absorbed dose – a dosimetric parameter, having
the greatest influence on the effect of radioiodine
( 131I) therapy; so far, there has been no method
of absorbed dose determination which would
provide total therapeutic success of treating
thyroid diseases with radioiodine; the values of
absorbed dose, as proposed by various authors,
have been determined empirically, and so: for
nodular goitre – 120-150 Gy [3], for Graves’
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disease – 60-80 Gy [2, 3]; recently, elevated
absorbed doses are more and more often used:
for Graves’ disease – 200-300 Gy [5, 6], for
nodular goitre – 150-300 Gy [7];
4) EHL  of  radioiodine  –  a combination  of  the
physical half-life and the biological half-life.
The EHL is the period of time during which the
activity of the isotope applied to the patient is
halved. The EHL is determined by measurements
of isotope activity above the studied organ and
performed under constant conditions. The EHL for
131I, administered in the form of sodium iodide
(NaI), is approximately 6 days, 8 days at the
maximum. In about 10-15% of patients, a very
short EHL period is observed, which indicates
a quick turnover of iodine in the thyroid. One of
the ways to extend EHL and, in consequence, the
presence of iodine in the thyroid, is an increase of
the biological half-life, since the physical half-life
is a constant value. This can be achieved by using
lithium carbonate. 
Lithium carbonate inhibits hormone release from
the thyroid gland, and suppresses the formation of
colloid drops and thyroglobulin (Tg) proteolysis,
stimulated  by  TSH  and  cyclic  adenosine
monophosphate (cAMP). The aforesaid element can
be  accumulated  in  the  thyroid  and,  after  its
concentration reaches a certain level, it may block
the synthesis of T4 and T3 at several stages of its
course. Those observations have brought about
lithium carbonate applications in combination with
radioiodine, leading to the observation that lithium
carbonate, when administered in combination 
with  131I, may reduce the recovery period from
hyperthyroidism [8].
The ability of lithium carbonate to suppress
iodine release from the thyroid is used in patients
with  a short  EHL  of  radioiodine  [9,  10].  The
application of lithium carbonate in the therapy
should  precede  radioiodine  administration  by
approximately 3-4 days, to be then continued for 
7 days after radioiodine therapy is completed. The
most common dose is 500-700 mg (10 mg/kg b.w.)
to obtain the concentration of 0.4-0.8 nmol/l in
blood. The administration of lithium carbonate,
continued for a few days as complementation of
radioiodine therapy, does not really provide any risk
of occurrence of any side effects. 
Patients with enhanced hyperthyroidism are
prepared  for  radioiodine  therapy  by  receiving
antithyroid drugs in order to decrease the resources
of thyroid hormones in the thyroid gland. This
approach  reduces  the  risk  of  exacerbation  of
hyperthyroidism symptoms after radioiodine therapy
and decreases the incidence of radiation-induced
thyroiditis. 
Antithyroid drugs are thionamide derivatives and
are divided into two groups:
• derivatives  of  thiouracil  –  propylthiouracil
(Thyrosan [Sun-Farm]);
• derivatives of imidazole – thiamazole (Metizol [ICN
Polfa-Rzesz￳w], Thyrozol [Merck]).
Typically, the treatment begins with the dose of
30-60 mg  of  thiamazole  or  400-600 mg  of
propylthiouracil per day, while after 4-8 weeks, the
doses are reduced to maintenance doses: 5-20 mg of
thiamazole or 50-200 mg of propylthiouracil per day. 
These drugs inhibit the initial stages of thyroid
hormone synthesis, exerting suppressive effects 
on iodine oxidation and organification, regulated
by thyroid peroxidase activity. They also inhibit 
the  binding  of  monoiodotyrosine  (MIT)  and
diiodotyrosine (DIT) particles into 3,5,3’-triiodo-
thyronine  and  the  binding  of  two  DIT  par-
ticles into 3,5,3’,5’-tetraiodothyronine. Moreover
they  directly  affect  Tg  structure  modification.
Thionamides  may  also  indirectly  modify  the
production of T3 and T4, thus affecting the growth
of follicular thyroid cells by suppression of the
proliferogenic effect of insulin-like growth factor
I on thyrocytes. Additionally, thiouracil derivatives
inhibit the transformation of T4 into T3 in peripheral
tissues. Because the discussed preparations do not
inhibit iodine transportation to the thyroid or block
the release of hormones stored in the thyroid,
control  of  the  thyroid  gland  is  not  regained
immediately – requiring, in the majority of cases,
a few weeks to be established. When the status of
euthyroidism or close to euthyroidism is obtained,
a few  days  before  radioiodine  administration,
antithyroid drugs should be withdrawn, as many
authors indicate their unfavourable effects on the
final outcome of radioiodine therapy [11]. They
explain this assumption by reference to the fact
that antithyroid drugs decrease, in general, iodine
uptake by the thyroid and, reducing the intrathyroid
iodine resources, they contribute to quick iodine
turnover  in  the  thyroid.  In  consequence,  the
effective half-life of radioiodine in the thyroid is
shorter,  thus  also  reducing  the  efficacy  of  131I
treatment. There are also other authors [12, 13] who
claim  that  Metizol,  in  contrast  to  Propycil
(Thyrosan), does not affect the final outcome of 131I
therapy. The discussions concern the issue of how
many  days  before  radioiodine  administration
antithyroid drugs should be withdrawn to regain
satisfactory iodine uptake by the thyroid. Some
authors think that the withdrawal of antithyroid
drugs  2  days  before  radioiodine  application
increases its effectiveness even by 50% by longer
EHL and increased iodine uptake [11, 14].
Also Kobe et al. [15], in a group of 571 patients
with Graves’ disease, withdrew antithyroid agents,
regardless of the preparation used (carbimazole,
methimazole,  propylthiouracil),  2  days  before
scheduled radioiodine therapy onset. 
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Kubota et al. [16] compared the efficacy of 131I
therapy after withdrawal of thyrostatic agents 
2 days before radioiodine application vs. 7 days
before the therapy onset, with FT4 concentration
measurement  after  24  h  from  the  isotope
administration. They demonstrated a significant
increase  of  FT4 in  the  group  of  patients  with
withdrawal of thyrostatics 7 days before radioiodine
therapy, with no statistical difference in the efficacy
of  therapy  between  the  groups.  The  authors
concluded that the 2-day break in administration
of thyrostatics is sufficient and advantageous,
especially in elderly patients and in those with
cardiovascular history – no aggravation of hyper-
thyroidism after 131I administration.
Other authors propose thyrostatic drugs to be
withdrawn 3-7 days before radioiodine treatment
[17-20].
In turn, a group of Danish authors [21] assume
that the application of propylthiouracil before 131I
therapy worsens its efficacy, despite withdrawal of
the thyrostatic agent 4 days before radioiodine
administration vs. the group of patients prepared
for 131I therapy with β-adrenergic blocking drugs
only. The same authors [22] unequivocally proved
worse efficacy of radioiodine in those patients who
had been administered thiamazole during the
peritherapeutic period vs. the group of patients in
whom the drug had been withdrawn 8 days before
isotope application. 
The studies of some of the above-mentioned
authors have been summarised in a collective work
by Walter et al. [23]. A lack of consensus appears
from  the  review,  regarding  the  time  point  of
thyrostatics’ withdrawal before radioiodine therapy,
while all the authors underline a negative influence
of the thyrostatics used on the final outcome of 131I
therapy. 
Radioactive iodine should not be used in patients
with high concentrations of free thyroid hormones
(FT3 and FT4) because of the risk of hyperthyroidism
exacerbation, caused by release of the hormones
into the circulation in the course of temporary
thyroiditis. The highest risk associated with these
patients  is  the  exacerbation  of  cardiological
problems. Sometimes, however, it is difficult to
obtain  normal  thyrometabolic  status  before
radioiodine therapy; there are patients in whom
even a short withdrawal of thyrostatics’ application
increases  the  severity  of  hyperthyroidism
symptoms. Therefore, in those patients, antithyroid
drugs are administered during the peritherapeutic
period of 131I administration. 
In sporadic cases, the enhancement of hyper-
thyroidism  is  manifested  as  a thyroid  crisis.
Therefore, in some of these patients, a few days
before radioiodine treatment, antithyroid drugs are
applied again in order to shorten the phase of
hyperthyroidism. It may, on one hand, weaken the
therapeutic effects of radioiodine [6, 18], while
providing, on the other hand, safety of the entire
therapy  application,  enabling  the  status  of
euthyroidism to be obtained earlier. 
Mijanhout et al. [24] monitored the applied
management after radioiodine therapy in 16 Dutch
hospitals. They found that only in one hospital were
no thyrostatic agents administered after 131I therapy,
in  two  hospitals  thyrostatic  agents  were
administered only when indicated, while in the
other  ones,  thyrostatics  were  applied  after
radioiodine therapy, their administration being
continued for several weeks. At our department,
thyrostatic agents are applied after radioiodine
treatment only in case of enhanced hyperthyroid
symptoms, in elderly patients with cardiological
disorders. 
Antithyroid drugs, especially thionamides, reveal
local immunosuppressive activity in the thyroid,
which is closely associated with their antioxidative
function.  Their  effects  include,  among  others,
reducing lymphocytic infiltrations in the thyroid and
decreasing  the  concentrations  of  antithyroid
autoantibodies. This, among other things, explains
the  higher  efficacy  of  thionamides  vs.  other
antithyroid  drugs  in  the  treatment  of  auto-
immunological diseases of the thyroid gland [25].
Antithyroid drugs may reduce the symptoms and
signs of Graves’ orbitopathy. On the other hand,
the use of these drugs may induce adverse effects.
Serious adverse symptoms are rarely observed 
(< 1%). The most dangerous is agranulocytosis,
which may rapidly develop and is usually revealed
during the first 3-4 months from therapy initiation.
Agranulocytosis is manifested by fever and infection
symptoms. The necessary therapy assumes the
withdrawal of antithyroid drugs, application of
antibiotics of broad spectrum of action and growth
factors,  necessary  to  stimulate  bone  marrow
regeneration. Usually, after 2-3 weeks of therapy,
the patients fully recover [26]. Hepatitis, vasculitis
and the lupus-like syndrome are rare but recognized
complications, demanding withdrawal of the drugs.
Side  effects,  milder  in  character,  are  more
commonly observed (1-5% of patients), including
pruritus, rash, transient granulocytopenia, fever,
arthralgia  and  gastric  symptoms.  All  these
symptoms may disappear spontaneously despite
the continuation of antithyroid treatment; however,
they usually require one thyrostatic drug to be
replaced by another. Also, cases of cross-hyper-
sensitivity are sometimes observed. 
Many authors have focussed attention on the
possibility  of  occurrence  or  exacerbation  of
orbitopathy in patients with Graves’ disease treated
with radioiodine [27, 28]. In order to prevent any
enhancement of the inflammatory process in the
Drugs and efficacy of radioiodine (131I) therapy 8 Arch Med Sci 1, February / 2010
orbital  cavity,  attempts  are  undertaken  at
prophylactic application of glucocorticosteroids 
[6, 18, 29, 30].
The anti-inflammatory and immunosuppressive
effects of glucocorticosteroids are the features used
in  the  treatment  of  orbitopathy;  glucocortico-
steroids  also  inhibit  the  synthesis  of  glyco-
aminoglycans  by  fibroblasts  [29].  It  has  been
demonstrated that properly treated and controlled
hyperthyroidism protects against the development
of unfavourable changes in the eye. Orbitopathy
progression has been observed in those patients
whose  status  of  hyperthyroidism  required
administration of several doses of radioiodine, in
comparison with those groups of patients in whom
hypothyroidism was induced already after the first
administered dose.
At present, two treatment protocols are used:
a few  months’  therapy  with  oral  glucocor-
ticosteroids, administered in gradually decreased
doses, or treatment with pulses of methylpre-
dnisolone. The former protocol involves prednisone
(Encorton,  Polfa-Pabianice)  administrations  in
a dose  of  1-2  mg/kg  b.w./day  for  6-8  weeks,
followed by dose decrease until total withdrawal.
It is effective, especially with regards to the changes
associated with connective tissue inflammation, as
among other effects it brings about quick pain
relief; it is also used in optic nerve neuropathy.
Unfortunately, the troubles related to eye muscles
and exophthalmos regress at a slower pace, and
often recur after dose reduction or drug withdrawal.
In  order  to  limit  the  commonly  known
complications and adverse effects of glucocorti-
costeroids, a treatment with methylprednisolone
pulses has been proposed at a dose of 0.5-1.0 g, to
be  administered  by  intravenous  infusion  for 
3 consecutive days of the week for 3-7 weeks. 
Corticosteroids  are  not  commonly  used  as
complementary  treatment  prior  to  radioiodine
therapy. However, there are some authors [31] who
obtained compensation of the thyrometabolic state
by means of antithyroid drugs only after prednisone
addition, which allowed performance of effective
radioiodine therapy. Other authors [32] believe that
the  use  of  corticosteroids  during  radioiodine
treatment is, from the prognostic point of view,
rather  negative  for  the  general  outcome  of
radioiodine therapy. In turn, other authors [33] found
that the use of corticosteroids had no effect on the
final therapeutic effect in hyperthyroid patients with
Graves’ disease. 
Corticosteroids are applied in the treatment of
thyroid crisis, being administered by intravenous
infusion. Their suppressive effect on hormone
release  from  the  thyroid  gland  and  on  the
conversion from T4 to T3 in peripheral tissues are
the two factors utilised in thyroid crisis therapy.
Thyroid crisis may also be treated with inorganic
iodides,  administered  as  Lugol’s  solution  or
saturated solution of potassium iodide (SSKI), due
to  its  property  of  instant  blocking  of  thyroid
hormone release from the gland. There are also
other  authors  [34,  35]  who  claim  that  the
administration  of  inorganic  iodine  during  the
peritherapeutic  period  of  treatment  with  131I
improves the efficacy of radioiodine therapy in
patients with hyperthyroidism. They also say that
the  administration  of  inorganic  iodine  in  the
peritherapeutic period of 131I treatment extends EHL
and, in consequence, increases the provided dose
of radioiodine. 
In specific cases of iodine-induced thyrotoxicosis,
e.g., in hyperthyroidism caused by amiodarone
administration, potassium perchlorate may be
applied. It is a substance which strongly suppresses
the  accumulation  of  iodides  in  the  thyroid  by
competitive inhibition of the iodine pump. This
agent, which should be administered in a dose of
1000  mg/day,  is  now  very  rarely  applied  for
hyperthyroidism  treatment,  as  its  long-term
administration may lead to irritation of the gastric
mucosa and toxic reactions. In clinical situations in
which – for cardiological reasons – it is not possible
to withdraw amiodarone, when thyroid functions
return to normal balance, an option of radical
treatment should be considered, e.g., by radioactive
iodine. It is possible in hyperthyroidism of type I. In
type II, resulting from thyroid destruction, iodine
uptake  is  usually  very  low,  which  precludes
radioiodine administration. One may, however, find
authors  [36]  who  succeeded  in  radioiodine
treatment in type II hyperthyroidism, induced by
amiodarone, obtaining in the eventual outcome
either euthyroidism or hypothyroidism. The authors
of the study applied, however, very high activities
of radioiodine (up to 80 mCi 131I), which are not
routinely used in the treatment of hyperthyroidism.
This raises even more doubts, as this type of
hyperthyroidism reveals a self-limiting character for
itself  and  may  thus  spontaneously  lead  to
hypothyroidism. 
Taking into account the adrenergic component of
thyrotoxicosis, various drugs from the group of
adrenergic antagonists are applied as com-plimentary
treatment of hyperthyroidism. β-Adrenergic receptor
blocking drugs (propranolol, metoprolol, atenolol,
nadolol) inhibit the increased sympathicomimetic
activity. Propranolol also reveals membranous activity,
decreases the activity of type I 5’-deiodinase and, in
consequence, increases the transformation of T4
into inactive reverse T3 (rT3), thereby causing T3
concentration reduction in the blood. This drug does
not have internal sympathicomimetic activity and
exerts  favourable  effects  on  the,  so-called,
peripheral symptoms of hyperthyrosis: tachycardia,
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hidrosis, and nervous irritability. It also reduces the
symptoms of fine tremor and eyelid retraction. If
there are no contraindications, propranolol is useful
in controlling hyperthyroidism symptoms, both
before and after radioiodine therapy, while waiting
for therapeutic results of administered radioiodine.
Propranolol is most often recommended in doses
of 30-120 mg per day. 
Radiotherapy  leads  to  regression  of  hyper-
thyroidism symptoms and to reduction of goitre
size,  but  is  associated  with  a possibility  of
hypothyroidism, the frequency of which increases
in time. In case of a lack of normalisation of thyroid
functions after 6 months from radioiodine therapy,
it is usually decided to give a subsequent dose of
radioiodine.
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